Purified Recombinant Human CD30 Ligand (Accession # P32971)
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Storage and Handling
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Country of Origin
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing CD30 Ligand. A suggested method would be to stain cells expressing CD30 Ligand with 0.25 µg per 1-2.5 x 106 cells in a total staining volume of ≤200 µl followed by PN:M1189.
Other Applications Reported In Literature ?
Neutralization: This antibody is useful for neutralization of Human CD30 Ligand bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human CD30 Ligand (at 1.0 ng/ml) is 1.0-4.0 µg/ml.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Mouse Anti-Human CD30 Ligand (Clone 116614) recognizes an epitope on Human CD30 Ligand. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. This antibody showed no cross-reactivity with rhCD27 Ligand, rmCD30 Ligand or rhCD40 Ligand.
The CD30 ligand is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. Recombinant CD30L has been shown to co-stimulate T cells and to act as a mitogen for Hodgkin's disease derived cell lines. The receptor for CD30L, CD30/ TNFRSF8/CD153, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis.
References & Citations
1. Croager, EJ. et al. (1997) Biochim. Biophys. Acta. 1353:231
2. Gruss, HJ. et al. (1994) Blood 83:1521
3. Wendtner, CM. et al. (1995) Cancer Res. 55:4157
4. Fischer, M. et al. (2006) J. Clin. Invest. 116:2748
5. Blazar, BR. et al. (2004) J. Immunol. 173:2933
Products are for research use only. Not for use in diagnostic or therapeutic procedures.